Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMJZYC)

• Drug Name: CH-223191 Drug Info
• Synonyms: 301326-22-7; CH 223191; CH223191; UNII-HYE7315Z4C; HYE7315Z4C; CHEMBL1743245; AhR Antagonist; 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide; 1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide; 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide; (E)-1-methyl-N-(2-methyl-4-(o-tolyldiazenyl)phenyl)-1H-pyrazole-5-carboxamide; 1-methyl-N-{2-methyl-4-[(E)-(2-methylphenyl)diazenyl]phenyl}-1H-pyrazole-5-carboxamide; 2-Methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide; CBDivE_007629; SCHEMBL363547; DTXSID5058698; AOB1977; EX-A771; SYN5007; CHEBI:125508; HMS3412G22; HMS3676G22; HMS3750E07; BCP12814; ZINC4762981; BDBM50525572; MFCD00377884; s7711; SBB081907; STK837883; 2-Methyl-2H-pyrazole-3-carboxylic acid-(2-methyl-4-o-tolyl-azophenyl)-amide; AKOS000629906; AKOS026750492; ZINC100550218; ZINC254429865; CCG-267843; CS-3905; MCULE-3225752823; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-((2-methylphenyl)azo)phenyl)-; 1H-Pyrazole-5-carboxamide, 1-methyl-N-(2-methyl-4-(2-(2-methylphenyl)diazenyl)phenyl)-; AC-32878; AS-16374; HY-12684; QC-11824; FT-0696668; X3558; J-017795; BRD-K22314899-001-01-6; Q27216129; Q27280162; 1-methyl-N-{2-methyl-4-[2-(2-methylphenyl)diazen-1-yl]phenyl}-1H-pyrazole-5-carboxamide; N-{2-methyl-4-[(2-methylphenyl)diazenyl]phenyl}(1-methylpyrazol-5-yl)carboxami de

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3091786
  ChEBI ID: CHEMBL125508
  CAS Number: CAS 301326-22-7
  TTD Drug ID: DMMJZYC

Molecule-Related Drug Atlas

Drug(s) Targeting Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[6]
Tapinarof	DMRPI2Q	Plaque psoriasis	EA90.0	Approved	[7]
RVT-505	DM3C9F8	Atopic dermatitis	EA80	Phase 2	[8]
IK-175	DMDU54Y	Urothelial carcinoma	2C92.0	Phase 1	[9]
BAY 2416964	DMD9N12	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
AT-177	DMJ02RH	Ulcerative colitis	DD71	Clinical trial	[11]
CB7993113	DMJUQ6E	Solid tumour/cancer	2A00-2F9Z	Preclinical	[12]
2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester	DMIS1G7	Glioma	2A00.0	Preclinical	[13]
6-Formylindolo[3,2-b]carbazole	DMN84RM	Dermatitis	EA80-EA89	Investigative	[14]

Drug(s) Affected By Phosphoglycerate kinase 1 (PGK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[15]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[16]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]

Drug(s) Affected By Bisphosphoglycerate mutase (BPGM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[25]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[28]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[31]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[34]

Drug(s) Affected By ATP-dependent 6-phosphofructokinase, muscle type (PFKM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[35]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[37]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[35]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[38]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[40]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[41]
Bardoxolone methyl	DMODA2X	Mixed connective tissue disease	4A43.3	Phase 3	[42]

Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[43]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[44]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[46]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[47]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[48]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[50]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[51]

Drug(s) Affected By Triosephosphate isomerase (TPI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[16]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[53]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[55]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[56]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]

Drug(s) Affected By Hyaluronan synthase 3 (HAS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[59]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[63]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[65]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[66]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[67]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[67]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[67]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[70]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[67]

Drug(s) Affected By Interstitial collagenase (MMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[66]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[73]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[74]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[75]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[76]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[77]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[78]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[79]

Drug(s) Affected By Plasminogen activator inhibitor 2 (SERPINB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[81]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[82]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[82]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[83]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[84]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[85]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[86]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]

Drug(s) Affected By Amino acid transporter heavy chain SLC3A2 (SLC3A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[87]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[70]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[50]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[88]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[88]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[89]

Drug(s) Affected By Catenin alpha-1 (CTNNA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[91]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[92]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[93]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[79]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[93]
Haloperidol	DM96SE0	Delirium		Approved	[46]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]

Drug(s) Affected By Glycerol-3-phosphate acyltransferase 3 (GPAT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[89]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[89]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[89]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[98]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[99]

Drug(s) Affected By Adhesion G-protein coupled receptor F1 (ADGRF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[100]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[28]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[102]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[103]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
QUERCITRIN	DM1DH96	Discovery agent	N.A.	Investigative	[104]

Drug(s) Affected By Solute carrier family 22 member 4 (SLC22A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[105]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[70]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[50]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[28]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[63]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[106]

Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[107]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[107]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[108]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[109]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[110]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[111]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[53]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[112]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[50]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[113]

Drug(s) Affected By Serine/arginine repetitive matrix protein 5 (SRRM5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]

Drug(s) Affected By Potassium channel subfamily K member 1 (KCNK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[95]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[116]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[116]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[117]

Drug(s) Affected By CCN family member 1 (CCN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[118]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[119]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[120]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[70]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[119]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[51]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[121]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[86]

Drug(s) Affected By Insulin-induced gene 1 protein (INSIG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[122]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[123]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[124]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[125]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[126]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[125]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[127]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[128]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[89]

Drug(s) Affected By MutS protein homolog 5 (MSH5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[129]
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[128]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[128]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[52]

Drug(s) Affected By Mitotic checkpoint protein BUB3 (BUB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[131]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[132]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[133]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[38]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[134]

Drug(s) Affected By Nuclear protein 1 (NUPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[135]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[136]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[137]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[135]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[135]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[135]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[138]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[136]

Drug(s) Affected By 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[128]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[128]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[139]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[40]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[117]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[140]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[140]

Drug(s) Affected By Src kinase-associated phosphoprotein 2 (SKAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[65]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[141]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[142]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[143]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[144]

Drug(s) Affected By TIP41-like protein (TIPRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[48]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[145]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[146]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[147]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[34]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[148]

Drug(s) Affected By GDH/6PGL endoplasmic bifunctional protein (H6PD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[149]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[150]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[151]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[151]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[152]

Drug(s) Affected By BAG family molecular chaperone regulator 2 (BAG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[122]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[65]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[153]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[154]

Drug(s) Affected By Tropomyosin alpha-1 chain (TPM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[48]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[16]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[155]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Dihydroartemisinin	DMBXVMZ	Malaria	1F40-1F45	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[99]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[156]
Bortezomib	DMNO38U	Leukemia		Approved	[157]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[158]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[159]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[160]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[161]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[162]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[81]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[67]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[163]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[164]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[67]

Drug(s) Affected By Proto-oncogene tyrosine-protein kinase Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosutinib	DMTI8YE	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[165]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[166]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[167]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[168]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[51]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[169]
Plicamycin	DM7C8YV	Hypercalcaemia	5B91.0	Approved	[170]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[171]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[171]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]

Drug(s) Affected By Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[87]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[88]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[88]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[88]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[141]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]

Drug(s) Affected By Homeobox protein engrailed-2 (EN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[64]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[116]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[116]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
Calphostin C	DM9X2D0	N. A.	N. A.	Terminated	[172]

Drug(s) Affected By CCN family member 2 (CCN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[173]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[124]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[119]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[175]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[176]

Drug(s) Affected By NK-tumor recognition protein (NKTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[177]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[178]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[102]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[144]

Drug(s) Affected By DNA damage-inducible transcript 3 protein (DDIT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Triacetin	DM0AEPG	Onychomycosis	EE12.1	Approved	[179]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[180]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[181]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[182]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[118]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[183]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[184]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[185]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]

Drug(s) Affected By Chymotrypsin-like protease CTRL-1 (CTRL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[91]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]
PMID28870136-Compound-48	DMPIM9L	N. A.	N. A.	Patented	[186]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[34]
Plumbagin	DM9BS50	Discovery agent	N.A.	Investigative	[187]

Drug(s) Affected By DNA-binding protein inhibitor ID-1 (ID1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[188]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[161]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[90]
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[189]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[190]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]

Drug(s) Affected By Neutral amino acid transporter A (SLC1A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[50]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[19]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[89]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[89]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[89]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[19]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[191]

Drug(s) Affected By Eukaryotic translation initiation factor 1A, X-chromosomal (EIF1AX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[85]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[192]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[178]
Indomethacin	DMSC4A7	Bursitis		Approved	[193]

Drug(s) Affected By Transcription factor SOX-9 (SOX9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[194]
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[70]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[195]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[65]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[128]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[86]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[196]

Drug(s) Affected By Isocitrate dehydrogenase subunit gamma, mitochondrial (IDH3G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[197]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[52]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[147]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[198]

Drug(s) Affected By Ephrin-A4 (EFNA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[199]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[139]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]

Drug(s) Affected By Heat shock-related 70 kDa protein 2 (HSPA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[200]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[70]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[201]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[202]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[121]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[85]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]

Drug(s) Affected By Protein jagged-1 (JAG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[203]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[125]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[204]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[205]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[191]

Drug(s) Affected By Septin-2 (SEPTIN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[206]
[3H]methyltrienolone	DMTSGOW	Discovery agent	N.A.	Investigative	[207]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[208]

Drug(s) Affected By Transcription elongation factor A protein 2 (TCEA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[91]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[209]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[86]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[210]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[210]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]

Drug(s) Affected By Homeobox protein TGIF1 (TGIF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[211]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[212]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[127]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[213]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[214]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]

Drug(s) Affected By Tubulin-specific chaperone C (TBCC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[152]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[215]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]

Drug(s) Affected By Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[87]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[124]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[125]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[216]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[46]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[217]

Drug(s) Affected By Manganese-dependent ADP-ribose/CDP-alcohol diphosphatase (ADPRM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[117]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[117]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]

Drug(s) Affected By Alpha-(1,3)-fucosyltransferase 11 (FUT11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[150]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[86]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[218]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[131]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]

Drug(s) Affected By Suppressor APC domain-containing protein 1 (SAPCD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[148]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[99]

Drug(s) Affected By Early estrogen-induced gene 1 protein (EEIG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[142]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[124]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[219]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[219]
Estriol	DMOEM2I	Hormone deficiency	5A61.1	Approved	[219]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[199]

Drug(s) Affected By Ribonuclease H2 subunit B (RNASEH2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[128]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[128]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[199]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[220]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[17]

Drug(s) Affected By Coiled-coil and C2 domain-containing protein 1A (CC2D1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[102]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[147]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[221]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[140]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[148]

Drug(s) Affected By Acylpyruvase FAHD1, mitochondrial (FAHD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[197]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[222]

Drug(s) Affected By Ferric-chelate reductase 1 (FRRS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[34]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[34]

Drug(s) Affected By Protein FAM43B (FAM43B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[86]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[223]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[210]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[210]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[144]

Drug(s) Affected By Tubulin polyglutamylase TTLL7 (TTLL7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[125]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[155]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[224]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[225]

Drug(s) Affected By GRB2-associated and regulator of MAPK protein 2 (GAREM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[91]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[64]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[103]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[226]

Drug(s) Affected By Coiled-coil domain-containing protein 186 (CCDC186)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[155]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Bortezomib	DMNO38U	Leukemia		Approved	[157]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[227]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[144]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]

Drug(s) Affected By Pleckstrin homology-like domain family B member 2 (PHLDB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[80]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[34]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[124]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[51]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[86]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[228]

Drug(s) Affected By Interferon regulatory factor 2-binding protein 1 (IRF2BP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[157]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[102]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[229]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]

Drug(s) Affected By TBC1 domain family member 21 (TBC1D21)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]

Drug(s) Affected By Protein FAM24B (FAM24B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[65]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[230]

Drug(s) Affected By Saccharopine dehydrogenase-like oxidoreductase (SCCPDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[211]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[65]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[46]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[178]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[231]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]

Drug(s) Affected By Polyhomeotic-like protein 3 (PHC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[232]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Bortezomib	DMNO38U	Leukemia		Approved	[157]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[38]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[233]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[140]

Drug(s) Affected By Large ribosomal subunit protein mL64 (GADD45GIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
COUMESTROL	DM40TBU	Discovery agent	N.A.	Investigative	[234]

Drug(s) Affected By Gasdermin-B (GSDMB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[178]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[64]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[95]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[235]

Drug(s) Affected By F-box only protein 30 (FBXO30)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[150]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[89]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[89]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[89]

Drug(s) Affected By E3 ubiquitin-protein ligase RNF217 (RNF217)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[65]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[65]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[236]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[99]

Drug(s) Affected By Minor histocompatibility antigen H13 (HM13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[202]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[238]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[239]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[117]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[239]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]

Drug(s) Affected By Alanine aminotransferase 2 (GPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[88]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[88]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[153]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[88]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]

Drug(s) Affected By Cyclic AMP-responsive element-binding protein 3-like protein 4 (CREB3L4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[192]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[233]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[192]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[117]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[131]

Drug(s) Affected By Ataxin-2-like protein (ATXN2L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[178]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[68]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[40]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[239]

Drug(s) Affected By Nectin-2 (NECTIN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[65]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[46]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[46]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[139]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[116]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]

Drug(s) Affected By Protein TMEPAI (PMEPA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[65]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[153]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[89]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[89]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[89]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[89]
Heroin diacetylmorphine	DMDBWHY	Neurological disorder	6B60	Approved	[240]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]

Drug(s) Affected By Insulin gene enhancer protein ISL-2 (ISL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[88]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[88]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[88]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[218]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[178]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[88]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[33]

Drug(s) Affected By Myotubularin-related protein 8 (MTMR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[241]

Drug(s) Affected By Sodium/bile acid cotransporter 4 (SLC10A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[242]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[243]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[65]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[244]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[99]

Drug(s) Affected By Enhancer of mRNA-decapping protein 3 (EDC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[68]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[89]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[68]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[245]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[246]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[140]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[140]

Drug(s) Affected By Mediator of RNA polymerase II transcription subunit 8 (MED8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[247]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[229]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[247]

Drug(s) Affected By Oxidoreductase NAD-binding domain-containing protein 1 (OXNAD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[147]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]

Drug(s) Affected By Conserved oligomeric Golgi complex subunit 8 (COG8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[248]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[221]

Drug(s) Affected By TOX high mobility group box family member 2 (TOX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[65]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[210]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[143]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[95]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[144]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[65]

Drug(s) Affected By Contactin-associated protein-like 3B (CNTNAP3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[218]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[249]

Drug(s) Affected By Endoplasmic reticulum-Golgi intermediate compartment protein 2 (ERGIC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[157]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[117]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[250]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[148]

Drug(s) Affected By Tribbles homolog 3 (TRIB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[124]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[88]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[19]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[251]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[88]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[252]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]

Drug(s) Affected By TSC22 domain family protein 3 (TSC22D3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[253]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[186]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[189]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[176]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[86]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[131]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[254]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[157]

Drug(s) Affected By Copine-1 (CPNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[87]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[87]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[46]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[210]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[210]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[52]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]

Drug(s) Affected By Plasma alpha-L-fucosidase (FUCA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[255]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[152]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[197]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]

Drug(s) Affected By Arginine/serine-rich protein 1 (RSRP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[51]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[256]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[68]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[64]

Drug(s) Affected By Oxysterol-binding protein-related protein 6 (OSBPL6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[51]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[210]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[210]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[115]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[257]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[258]

Drug(s) Affected By Transmembrane protein 168 (TMEM168)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[34]
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[155]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]

Drug(s) Affected By Autophagy protein 5 (ATG5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[259]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[260]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[261]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[262]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[263]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[264]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[265]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[266]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[144]

Drug(s) Affected By Histone-lysine N-methyltransferase EHMT1 (EHMT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[267]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[268]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[68]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[269]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[144]
YM155	DM5Q1W4	Breast cancer	2C60-2C65	Phase 2	[270]

Drug(s) Affected By Sp110 nuclear body protein (SP110)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[91]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[97]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[232]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[271]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]

Drug(s) Affected By Transcriptional and immune response regulator (TCIM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[173]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[79]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[272]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[128]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[128]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]

Drug(s) Affected By Protein kish-B (TMEM167B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[250]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[148]

Drug(s) Affected By Nucleotide triphosphate diphosphatase NUDT15 (NUDT15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[116]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[116]
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[273]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[116]

Drug(s) Affected By DNA damage-inducible transcript 4 protein (DDIT4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[122]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[274]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[203]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[275]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[249]

Drug(s) Affected By Inhibitor of growth protein 3 (ING3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[252]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[155]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[276]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[277]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[30]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[144]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[278]

Drug(s) Affected By E3 ubiquitin-protein ligase MARCHF2 (MARCHF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[161]
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[79]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[144]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[147]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 10D (TNFRSF10D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[279]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[249]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[95]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[131]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[280]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[154]

Drug(s) Affected By Rap guanine nucleotide exchange factor-like 1 (RAPGEFL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[281]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[281]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[60]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[155]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Mestranol	DMG3F94	Contraception	QA21	Approved	[281]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[281]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[282]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[210]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[283]

Drug(s) Affected By SERTA domain-containing protein 3 (SERTAD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[26]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[268]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[199]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[38]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[147]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[32]

Drug(s) Affected By Axin-2 (AXIN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[65]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[285]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[286]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[287]

Drug(s) Affected By Chloride intracellular channel protein 4 (CLIC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[209]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[288]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[176]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[36]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[46]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]

Drug(s) Affected By Histone H2AX (H2AX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[289]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[290]
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[291]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[292]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[293]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[294]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[295]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[296]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[297]

Drug(s) Affected By Aryl hydrocarbon receptor nuclear translocator (ARNT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[298]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[91]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[299]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[300]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[4]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[192]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[287]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[64]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]

Drug(s) Affected By Cytochrome c (CYCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[301]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[302]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[303]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[304]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[305]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[306]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[167]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[307]
Pefloxacin	DM49IGF	Gonococcal urethritis	1A70.0Y	Approved	[308]

Drug(s) Affected By DNA polymerase kappa (POLK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[309]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[310]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[276]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[199]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[39]
Guanine	DMIWLJE	N. A.	N. A.	Phase 3	[311]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[229]
MK-886	DMT0O7H	Asthma	CA23	Discontinued in Phase 2	[312]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aryl hydrocarbon receptor (AHR)	TT037IE	AHR_HUMAN	Antagonist	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2)	OTG7NW98	F262_HUMAN	Gene/Protein Processing	[2]
Acylpyruvase FAHD1, mitochondrial (FAHD1)	OTSZJNPR	FAHD1_HUMAN	Gene/Protein Processing	[2]
Adhesion G-protein coupled receptor F1 (ADGRF1)	OTRAOBYH	AGRF1_HUMAN	Gene/Protein Processing	[3]
Alanine aminotransferase 2 (GPT2)	OTS5VF7N	ALAT2_HUMAN	Gene/Protein Processing	[2]
Alpha-(1,3)-fucosyltransferase 11 (FUT11)	OTD0CDN5	FUT11_HUMAN	Gene/Protein Processing	[2]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Gene/Protein Processing	[3]
Arginine/serine-rich protein 1 (RSRP1)	OTOAZLCL	RSRP1_HUMAN	Gene/Protein Processing	[2]
Aryl hydrocarbon receptor nuclear translocator (ARNT)	OTMSIEZY	ARNT_HUMAN	Gene/Protein Processing	[4]
Ataxin-2-like protein (ATXN2L)	OTP5M3R9	ATX2L_HUMAN	Gene/Protein Processing	[2]
ATP-dependent 6-phosphofructokinase, muscle type (PFKM)	OT1QY9JM	PFKAM_HUMAN	Gene/Protein Processing	[5]

References

• [1] Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8.
• [2] Adaptive changes in global gene expression profile of lung carcinoma A549 cells acutely exposed to distinct types of AhR ligands. Toxicol Lett. 2018 Aug;292:162-174.
• [3] The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines. Mol Carcinog. 2014 Oct;53(10):765-76.
• [4] Ligand-independent activation of AhR by hydroquinone mediates benzene-induced hematopoietic toxicity. Chem Biol Interact. 2022 Mar 1;355:109845. doi: 10.1016/j.cbi.2022.109845. Epub 2022 Feb 4.
• [5] 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated production of reactive oxygen species is an essential step in the mechanism of action to accelerate human keratinocyte differentiation. Toxicol Sci. 2013 Mar;132(1):235-49.
• [6] A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
• [7] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215272.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of Ikena Oncology.
• [10] ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of Azora Therapeutics
• [12] In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov;86(5):593-608.
• [13] 1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int. 2020 Oct 3;2020:2616930.
• [14] 6-Formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression. Chem Biol Interact. 2018 May 25;288:83-90.
• [15] PGK1 induction by a hydrogen peroxide treatment is suppressed by antioxidants in human colon carcinoma cells. Biosci Biotechnol Biochem. 2008 Jul;72(7):1799-808. doi: 10.1271/bbb.80079. Epub 2008 Jul 7.
• [16] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [17] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [18] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [19] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [20] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [21] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [22] Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.
• [23] Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells. Chem Res Toxicol. 2015 Oct 19;28(10):1903-13. doi: 10.1021/acs.chemrestox.5b00105. Epub 2015 Sep 21.
• [24] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [25] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [26] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [27] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [28] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [29] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [30] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [31] Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: microarray gene expression analyses. Mutat Res. 2005 Dec 11;591(1-2):198-211.
• [32] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [33] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [34] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [35] Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. Chem Biol Interact. 2015 May 25;233:147-56. doi: 10.1016/j.cbi.2015.03.028. Epub 2015 Apr 8.
• [36] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [37] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [38] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [39] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [40] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [41] Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie. 2013 Jun;95(6):1336-43. doi: 10.1016/j.biochi.2013.02.013. Epub 2013 Feb 27.
• [42] Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenocarcinoma via targeting SLC1A5. J Biochem Mol Toxicol. 2022 Nov;36(11):e23192. doi: 10.1002/jbt.23192. Epub 2022 Aug 5.
• [43] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [44] Insulin regulation of hexose transport in mouse 3T3-L1 cells expressing the human HepG2 glucose transporter. J Biol Chem. 1990 Nov 25;265(33):20106-16.
• [45] Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun. 2001 Jan 26;280(3):664-74. doi: 10.1006/bbrc.2000.4216.
• [46] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [47] Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. Toxicol Lett. 2009 Jan 30;184(2):81-4. doi: 10.1016/j.toxlet.2008.10.017. Epub 2008 Oct 28.
• [48] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [49] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [50] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [51] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [52] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [53] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [54] Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. Int J Cancer. 2004 Mar 20;109(2):220-9. doi: 10.1002/ijc.11692.
• [55] Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells. Biol Pharm Bull. 2007 Feb;30(2):247-53. doi: 10.1248/bpb.30.247.
• [56] Protein profile in neuroblastoma cells incubated with S- and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LC-MS/MS analysis: possible action of induced proteins on Alzheimer's disease. Proteomics. 2008 Apr;8(8):1595-607. doi: 10.1002/pmic.200700556.
• [57] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [58] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [59] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [60] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [61] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [62] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [63] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [64] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [65] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [66] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [67] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [68] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [69] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [70] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [71] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [72] Oxidative Stress-Protective and Anti-Melanogenic Effects of Loliolide and Ethanol Extract from Fresh Water Green Algae, Prasiola japonica. Int J Mol Sci. 2018 Sep 18;19(9):2825. doi: 10.3390/ijms19092825.
• [73] The effects of a novel synthetic retinoid, seletinoid G, on the expression of extracellular matrix proteins in aged human skin in vivo. Clin Chim Acta. 2005 Dec;362(1-2):161-9. doi: 10.1016/j.cccn.2005.06.016. Epub 2005 Aug 1.
• [74] Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum. 2002 Nov;46(11):3034-40. doi: 10.1002/art.10617.
• [75] Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler Thromb Vasc Biol. 2007 May;27(5):1043-9. doi: 10.1161/ATVBAHA.107.139881. Epub 2007 Feb 15.
• [76] Quercetin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells through extracellular signal-regulated kinase. Arch Biochem Biophys. 2001 Jul 1;391(1):72-8. doi: 10.1006/abbi.2001.2402.
• [77] Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors. Clin Pharmacol Ther. 2006 Apr;79(4):303-15. doi: 10.1016/j.clpt.2005.12.306.
• [78] Interaction between the aryl hydrocarbon receptor and retinoic acid pathways increases matrix metalloproteinase-1 expression in keratinocytes. J Biol Chem. 2004 Jun 11;279(24):25284-93. doi: 10.1074/jbc.M402168200. Epub 2004 Apr 9.
• [79] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [80] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [81] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [82] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [83] [Effects of As2O3 on tissue factor, plasminogen activator inhibitor-1 and -2 expression in NB4, HL-60 and THP-1 cells]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003 Oct;34(4):645-9.
• [84] Effects of aspirin on metastasis-associated gene expression detected by cDNA microarray. Acta Pharmacol Sin. 2004 Oct;25(10):1327-33.
• [85] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [86] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [87] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [88] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [89] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [90] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [91] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [92] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [93] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [94] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [95] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [96] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [97] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [98] Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
• [99] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [100] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [101] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [102] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [103] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [104] Molecular mechanisms of quercitrin-induced apoptosis in non-small cell lung cancer. Arch Med Res. 2014 Aug;45(6):445-54.
• [105] Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
• [106] Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
• [107] Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
• [108] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
• [109] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [110] ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
• [111] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [112] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [113] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.
• [114] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [115] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [116] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [117] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [118] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [119] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [120] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [121] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [122] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [123] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [124] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [125] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [126] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [127] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [128] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [129] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [130] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [131] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [132] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [133] Nuclear proteome analysis of cisplatin-treated HeLa cells. Mutat Res. 2010 Sep 10;691(1-2):1-8. doi: 10.1016/j.mrfmmm.2010.06.002. Epub 2010 Jun 9.
• [134] Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell Biol. 2004 Nov;23(11):769-76.
• [135] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [136] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [137] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [138] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [139] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [140] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [141] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [142] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [143] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [144] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [145] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [146] Gene expression in human hippocampus from cocaine abusers identifies genes which regulate extracellular matrix remodeling. PLoS One. 2007 Nov 14;2(11):e1187. doi: 10.1371/journal.pone.0001187.
• [147] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [148] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [149] Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
• [150] Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
• [151] Testosterone stimulates adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in a depot-specific manner in children. J Clin Endocrinol Metab. 2010 Jul;95(7):3300-8.
• [152] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [153] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [154] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [155] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [156] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [157] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [158] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [159] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [160] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [161] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [162] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [163] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [164] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [165] SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006 Feb 15;66(4):2279-86. doi: 10.1158/0008-5472.CAN-05-2057.
• [166] Selective activation of Src family kinases and JNK by low levels of chromium(VI). Toxicol Appl Pharmacol. 2003 Aug 1;190(3):214-23. doi: 10.1016/s0041-008x(03)00188-1.
• [167] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [168] Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol. 2014 Feb 1;87(3):424-34. doi: 10.1016/j.bcp.2013.11.008. Epub 2013 Nov 23.
• [169] Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem. 2015 Jun 19;290(25):15799-15811. doi: 10.1074/jbc.M115.641167. Epub 2015 May 11.
• [170] Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem Biol Interact. 2010 Jan 5;183(1):181-6. doi: 10.1016/j.cbi.2009.09.018.
• [171] The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
• [172] Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7516-21. doi: 10.1073/pnas.0610299104. Epub 2007 Apr 23.
• [173] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [174] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [175] The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
• [176] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [177] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [178] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [179] Induction of CCAAT/enhancer-binding protein-homologous protein by cigarette smoke through the superoxide anion-triggered PERK-eIF2 pathway. Toxicology. 2011 Sep 5;287(1-3):105-12. doi: 10.1016/j.tox.2011.06.005. Epub 2011 Jun 15.
• [180] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [181] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [182] Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
• [183] High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
• [184] Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci. 2014 Jan;137(1):234-48. doi: 10.1093/toxsci/kft232. Epub 2013 Oct 17.
• [185] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [186] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [187] Plumbagin induces paraptosis in cancer cells by disrupting the sulfhydryl homeostasis and proteasomal function. Chem Biol Interact. 2019 Sep 1;310:108733. doi: 10.1016/j.cbi.2019.108733. Epub 2019 Jul 2.
• [188] Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol. 2014 Oct;171(19):4464-77. doi: 10.1111/bph.12803. Epub 2014 Sep 5.
• [189] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [190] Study of As(2)O(3) regulating proliferation and apoptosis of Tca8113 cells by inhibiting the expression of Id-1. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1932-1937. doi: 10.1080/21691401.2019.1613419.
• [191] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [192] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [193] Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
• [194] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [195] The aryl hydrocarbon receptor activates the retinoic acid receptoralpha through SMRT antagonism. Biochimie. 2006 Mar-Apr;88(3-4):387-97. doi: 10.1016/j.biochi.2005.11.007. Epub 2005 Dec 7.
• [196] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [197] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [198] Ochratoxin a lowers mRNA levels of genes encoding for key proteins of liver cell metabolism. Cancer Genomics Proteomics. 2008 Nov-Dec;5(6):319-32.
• [199] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [200] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [201] D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
• [202] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [203] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [204] How benzene and its metabolites affect human marrow derived mesenchymal stem cells. Toxicol Lett. 2012 Oct 17;214(2):145-53. doi: 10.1016/j.toxlet.2012.08.015. Epub 2012 Aug 30.
• [205] NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
• [206] Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730. doi: 10.1016/j.envint.2021.106730. Epub 2021 Jun 27.
• [207] Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells. Proteomics. 2007 Jan;7(1):47-63.
• [208] Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci. 2002 Mar 1;70(15):1821-39.
• [209] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [210] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [211] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [212] Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells. Biochem J. 2011 Sep 1;438(2):349-58. doi: 10.1042/BJ20101653.
• [213] Hepatocyte growth factor receptor signaling mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular mesangial cells. Am J Pathol. 2005 Oct;167(4):947-57. doi: 10.1016/S0002-9440(10)61185-6.
• [214] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [215] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [216] Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res. 2009 Jun;8(6):3006-19.
• [217] In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006 Mar 28;5:13.
• [218] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [219] Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol. 2004 Feb;18(2):402-11. doi: 10.1210/me.2003-0202. Epub 2003 Nov 6.
• [220] Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
• [221] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [222] Transcriptomic alterations induced by Ochratoxin A in rat and human renal proximal tubular in vitro models and comparison to a rat in vivo model. Arch Toxicol. 2012 Apr;86(4):571-89.
• [223] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [224] Cellular reactions to long-term volatile organic compound (VOC) exposures. Sci Rep. 2016 Dec 1;6:37842. doi: 10.1038/srep37842.
• [225] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [226] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [227] Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 2006 Mar 1;66(5):2765-77.
• [228] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [229] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [230] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [231] 5-Fluorouracil up-regulates interferon pathway gene expression in esophageal cancer cells. Anticancer Res. 2005 Sep-Oct;25(5):3271-8.
• [232] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [233] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [234] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [235] The MT1G Gene in LUHMES Neurons Is a Sensitive Biomarker of Neurotoxicity. Neurotox Res. 2020 Dec;38(4):967-978. doi: 10.1007/s12640-020-00272-3. Epub 2020 Sep 1.
• [236] Bisphenol A and bisphenol S induce distinct transcriptional profiles in differentiating human primary preadipocytes. PLoS One. 2016 Sep 29;11(9):e0163318.
• [237] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [238] Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 2006 Apr 3;7:68. doi: 10.1186/1471-2164-7-68.
• [239] Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells. Mol Carcinog. 2006 Oct;45(10):752-63.
• [240] Distinctive profiles of gene expression in the human nucleus accumbens associated with cocaine and heroin abuse. Neuropsychopharmacology. 2006 Oct;31(10):2304-12. doi: 10.1038/sj.npp.1301089. Epub 2006 May 3.
• [241] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [242] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [243] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [244] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [245] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [246] Gene expression changes in human prostate carcinoma cells exposed to genotoxic and nongenotoxic aryl hydrocarbon receptor ligands. Toxicol Lett. 2011 Oct 10;206(2):178-88.
• [247] The genomic response of Ishikawa cells to bisphenol A exposure is dose- and time-dependent. Toxicology. 2010 Apr 11;270(2-3):137-49. doi: 10.1016/j.tox.2010.02.008. Epub 2010 Feb 17.
• [248] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [249] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [250] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [251] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [252] Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
• [253] Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell. 2006 Nov 3;24(3):341-54. doi: 10.1016/j.molcel.2006.10.019.
• [254] Hydrocortisone enhances the barrier properties of HBMEC/ci, a brain microvascular endothelial cell line, through mesenchymal-to-endothelial transition-like effects. Fluids Barriers CNS. 2015 Mar 5;12:7. doi: 10.1186/s12987-015-0003-0. eCollection 2015.
• [255] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [256] Real-time monitoring of cisplatin-induced cell death. PLoS One. 2011;6(5):e19714. doi: 10.1371/journal.pone.0019714. Epub 2011 May 16.
• [257] Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014 Apr 23;14:283.
• [258] Dose- and time-dependent transcriptional response of Ishikawa cells exposed to genistein. Toxicol Sci. 2016 May;151(1):71-87.
• [259] EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
• [260] Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. Oxid Med Cell Longev. 2018 Mar 18;2018:1482795. doi: 10.1155/2018/1482795. eCollection 2018.
• [261] Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway. Biochem Biophys Res Commun. 2018 Jan 29;496(1):167-175. doi: 10.1016/j.bbrc.2018.01.018. Epub 2018 Jan 4.
• [262] TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
• [263] Inhibition of autophagy enhances Hydroquinone-induced TK6 cell death. Toxicol In Vitro. 2017 Jun;41:123-132. doi: 10.1016/j.tiv.2017.02.024. Epub 2017 Mar 2.
• [264] AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia. Chem Biol Interact. 2020 Jan 5;315:108888. doi: 10.1016/j.cbi.2019.108888. Epub 2019 Nov 2.
• [265] Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe. 2009 Sep 17;6(3):231-43. doi: 10.1016/j.chom.2009.08.004.
• [266] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [267] Oxidative stress-induced epigenetic changes associated with malignant transformation of human kidney epithelial cells. Oncotarget. 2017 Feb 14;8(7):11127-11143. doi: 10.18632/oncotarget.12091.
• [268] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [269] Effects of chronic exposure to arsenic and estrogen on epigenetic regulatory genes expression and epigenetic code in human prostate epithelial cells. PLoS One. 2012;7(8):e43880. doi: 10.1371/journal.pone.0043880. Epub 2012 Aug 27.
• [270] YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells. PLoS One. 2017 Aug 7;12(8):e0182149. doi: 10.1371/journal.pone.0182149. eCollection 2017.
• [271] Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
• [272] Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
• [273] A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014 Sep;46(9):1017-20. doi: 10.1038/ng.3060. Epub 2014 Aug 10.
• [274] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [275] Identification of troglitazone responsive genes: induction of RTP801 during troglitazone-induced apoptosis in Hep 3B cells. BMB Rep. 2010 Sep;43(9):599-603. doi: 10.5483/BMBRep.2010.43.9.599.
• [276] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [277] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [278] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [279] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [280] Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids. Toxicol Mech Methods. 2023 Jun;33(5):401-410. doi: 10.1080/15376516.2022.2156005. Epub 2022 Dec 19.
• [281] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [282] DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009 May 14;28(19):2046-50. doi: 10.1038/onc.2009.62. Epub 2009 Apr 13.
• [283] Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
• [284] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [285] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [286] Estrogen receptor alpha (ER)-mediated coregulator binding and gene expression discriminates the toxic ER agonist diethylstilbestrol (DES) from the endogenous ER agonist 17-estradiol (E2). Cell Biol Toxicol. 2020 Oct;36(5):417-435. doi: 10.1007/s10565-020-09516-6. Epub 2020 Feb 22.
• [287] A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther. 2010 Feb;9(2):311-8. doi: 10.1158/1535-7163.MCT-09-0693. Epub 2010 Jan 26.
• [288] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [289] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [290] Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. J Toxicol Sci. 2015 Jun;40(3):329-38. doi: 10.2131/jts.40.329.
• [291] Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
• [292] Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
• [293] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [294] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [295] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [296] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [297] The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44. doi: 10.1016/j.dnarep.2003.10.014.
• [298] Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol. 2006 Nov;70(5):1664-71. doi: 10.1124/mol.106.025817. Epub 2006 Jul 31.
• [299] Single and concerted effects of benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line Caco-2. Toxicol In Vitro. 2011 Apr;25(3):671-83.
• [300] Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
• [301] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [302] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [303] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [304] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [305] K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012 Apr;26(3):429-34. doi: 10.1016/j.tiv.2012.01.013. Epub 2012 Jan 17.
• [306] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [307] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [308] Under ambient UVA exposure, pefloxacin exhibits both immunomodulatory and genotoxic effects via multiple mechanisms. J Photochem Photobiol B. 2018 Jan;178:593-605. doi: 10.1016/j.jphotobiol.2017.12.014. Epub 2017 Dec 15.
• [309] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [310] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
• [311] Analysis of nucleotide insertion opposite 2,2,4-triamino-5(2H)-oxazolone by eukaryotic B- and Y-family DNA polymerases. Chem Res Toxicol. 2015 Jun 15;28(6):1307-16. doi: 10.1021/acs.chemrestox.5b00114. Epub 2015 Jun 3.
• [312] Leukotriene biosynthesis inhibitor MK886 impedes DNA polymerase activity. Chem Res Toxicol. 2013 Feb 18;26(2):221-32. doi: 10.1021/tx300392m. Epub 2013 Jan 31.